Gut microbiota of obese subjects with Prader-Willi syndrome is linked to metabolic health.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
07 2020
Historique:
received: 20 06 2019
revised: 20 09 2019
accepted: 23 09 2019
pubmed: 16 10 2019
medline: 17 2 2021
entrez: 16 10 2019
Statut: ppublish

Résumé

The gut microbiota has been implicated in the aetiology of obesity and associated comorbidities. Patients with Prader-Willi syndrome (PWS) are obese but partly protected against insulin resistance. We hypothesised that the gut microbiota of PWS patients differs from that of non-genetically obese controls and correlate to metabolic health. Therefore, here we used PWS as a model to study the role of gut microbiota in the prevention of metabolic complications linked to obesity. We conducted a case-control study with 17 adult PWS patients and 17 obese subjects matched for body fat mass index, gender and age. The subjects were metabolically characterised and faecal microbiota was profiled by 16S ribosomal RNA gene sequencing. The patients' parents were used as a non-obese control group. Stool samples from two PWS patients and two obese controls were used for faecal microbiota transplantations in germ-free mice to examine the impact of the microbiota on glucose metabolism. The composition of the faecal microbiota in patients with PWS differed from that of obese controls, and was characterised by higher phylogenetic diversity and increased abundance of several taxa such as The gut microbiota of PWS patients is similar to that of their non-obese parents and might play a role for the protection of PWS patients from metabolic complications.

Identifiants

pubmed: 31611297
pii: gutjnl-2019-319322
doi: 10.1136/gutjnl-2019-319322
pmc: PMC7306984
doi:

Substances chimiques

RNA, Ribosomal, 16S 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1229-1238

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: FB is in the Scientific Advisory Board of MetaboGen, Sweden.

Références

Nat Med. 2017 Jan;23(1):107-113
pubmed: 27892954
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1491-1501
pubmed: 29409054
Nat Rev Genet. 2017 Dec;18(12):731-748
pubmed: 28989171
Nutrition. 2003 Jul-Aug;19(7-8):597-604
pubmed: 12831945
J Clin Endocrinol Metab. 2011 Jan;96(1):E225-32
pubmed: 20962018
Metabolism. 2019 Mar;92:51-60
pubmed: 30458177
BMC Public Health. 2013 Jul 03;13:629
pubmed: 23819808
Int J Obes (Lond). 2013 Sep;37(9):1198-203
pubmed: 23318724
Nature. 2013 Aug 29;500(7464):585-8
pubmed: 23985875
Genome Med. 2016 Feb 17;8(1):17
pubmed: 26884067
J Clin Endocrinol Metab. 2015 Mar;100(3):850-9
pubmed: 25478934
Gut. 2016 Mar;65(3):426-36
pubmed: 26100928
Genome Med. 2017 Nov 28;9(1):103
pubmed: 29183332
Gastroenterology. 2010 May;138(5):1772-82
pubmed: 20152836
Diabetologia. 2018 Apr;61(4):810-820
pubmed: 29379988
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23
pubmed: 15505215
Growth Horm IGF Res. 2010 Jun;20(3):179-84
pubmed: 20199883
Clin Endocrinol (Oxf). 2007 Dec;67(6):944-51
pubmed: 17666087
mBio. 2016 Aug 23;7(4):
pubmed: 27555308
Obesity (Silver Spring). 2012 Sep;20(9):1866-70
pubmed: 22193922
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
Nat Microbiol. 2016 Aug 08;1(10):16131
pubmed: 27670113
Cell Metab. 2017 Oct 3;26(4):611-619.e6
pubmed: 28978426
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Nat Med. 2017 Jul;23(7):859-868
pubmed: 28628112
Obesity (Silver Spring). 2006 Oct;14(10):1685-90
pubmed: 17062796
Cell. 2014 Nov 6;159(4):789-99
pubmed: 25417156
mBio. 2017 Sep 19;8(5):
pubmed: 28928206
Nature. 2009 Jan 22;457(7228):480-4
pubmed: 19043404
Nat Commun. 2019 Oct 3;10(1):4505
pubmed: 31582752
Gut. 2019 Jan;68(1):70-82
pubmed: 29899081
Annu Rev Med. 2005;56:443-58
pubmed: 15660521
Nature. 1997 Jun 26;387(6636):903-8
pubmed: 9202122
Clin Genet. 2005 Mar;67(3):230-9
pubmed: 15691361
FASEB J. 2010 Dec;24(12):4948-59
pubmed: 20724524
Curr Genomics. 2011 May;12(3):204-15
pubmed: 22043168
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Front Genet. 2015 Mar 19;6:81
pubmed: 25852737
Gut Microbes. 2016 Jul 3;7(4):302-312
pubmed: 27223845
FASEB J. 2018 Apr 27;:fj201800052RR
pubmed: 29957059
EBioMedicine. 2015 Jul 10;2(8):968-84
pubmed: 26425705
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71
pubmed: 23671105
J Clin Endocrinol Metab. 2016 Dec;101(12):4895-4903
pubmed: 27662437
Nature. 2013 Jun 6;498(7452):99-103
pubmed: 23719380
Clin Microbiol Rev. 2007 Oct;20(4):593-621
pubmed: 17934076
Science. 2017 Aug 11;357(6351):570-575
pubmed: 28798125

Auteurs

Lisa M Olsson (LM)

The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Christine Poitou (C)

INSERM, Nutrition and obesities; systemic approaches (NutriOmics) research Unit, Sorbonne Universite, Paris, Île-de-France, France.
Assistance Publique-Hôpitaux de Paris, Reference Center for Rare Diseases (Prader-Willi Syndrome), Nutrition Department, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France.

Valentina Tremaroli (V)

The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Muriel Coupaye (M)

Assistance Publique-Hôpitaux de Paris, Reference Center for Rare Diseases (Prader-Willi Syndrome), Nutrition Department, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France.

Judith Aron-Wisnewsky (J)

INSERM, Nutrition and obesities; systemic approaches (NutriOmics) research Unit, Sorbonne Universite, Paris, Île-de-France, France.
Assistance Publique-Hôpitaux de Paris, Reference Center for Rare Diseases (Prader-Willi Syndrome), Nutrition Department, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France.

Fredrik Bäckhed (F)

The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology and Enteroendocrinology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

Karine Clément (K)

INSERM, Nutrition and obesities; systemic approaches (NutriOmics) research Unit, Sorbonne Universite, Paris, Île-de-France, France Robert.Caesar@wlab.gu.se karine.clement@inserm.fr.
Assistance Publique-Hôpitaux de Paris, Reference Center for Rare Diseases (Prader-Willi Syndrome), Nutrition Department, University Hospital Pitié Salpêtrière, Paris, Île-de-France, France.

Robert Caesar (R)

The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Robert.Caesar@wlab.gu.se karine.clement@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH